检索结果-南通市图书馆

Chinese Chemical Letters 2012年第6期23卷 753-756页

作者： xue rong yao fang chen zhao xia guo jian yu Key Laboratory of Advanced Materials （MOE） Department of Chemical Engineering Tsinghua University Beijing 100084 China

Polypropylene/poly（butyl methacrylate）（PP/PBMA） blends were prepared by diffusion and subseqtuent polymerization＇of butyl methacrylate （BMA） in commercial isotactic polypropylene （iPP） pellets. The diffusion kinetics, diametrical distribution of PBMA in a pellet and phase morphology of a typical PP/PBMA blend were investigated.

关键词： Polypropylene Poly(butyl methacrylate) Diffusion Blend

在线全文

学校读者我要写书评

暂无评论

苯乙烯对高密度聚乙烯的扩散聚合行为研究

高分子学报 2016年第12期26卷 1717-1723页

作者：陈放姚雪容郭朝霞于建清华大学化工系先进材料教育部重点实验室北京100084

针对苯乙烯（St）对高密度聚乙烯（HDPE）的扩散聚合行为,及其产物粒子中聚苯乙烯（PS）的分布和形态特征进行了研究.结果表明：在70～90℃的扩散温度条件下,St对HDPE的扩散行为符合Fickian扩散的特征,且在90℃下当引发剂的过氧化苯甲酰... 详细信息

针对苯乙烯（St）对高密度聚乙烯（HDPE）的扩散聚合行为,及其产物粒子中聚苯乙烯（PS）的分布和形态特征进行了研究.结果表明：在70～90℃的扩散温度条件下,St对HDPE的扩散行为符合Fickian扩散的特征,且在90℃下当引发剂的过氧化苯甲酰（BPO）添加量在St的0.5 wt%～1 wt%之间时,HDPE粒料中PS含量将达到11 wt%,而当BPO大过量添加至5 wt%时PS的含量将达到16 wt%左右的最大值;无论BPO的添加量如何改变,HDPE粒料中的PS分布曲线均呈＂M＂形的形态,其峰值出现在距粒料表面200μm附近的区域且和HDPE粒料的结晶结构有关,但在HDPE粒料中生成的所有PS分散相的平均尺寸均小于100 nm;BPO添加量为0.5 wt%的体系即使在熔融挤出后,其PS分散相也仅略微发生聚集而不发生显著的聚并,呈现出一种类似于糍米团的复合结构,且其尺度分布在数十至200 nm的范围内;在BPO添加量为0.5 wt%的体系中,PS分散相和HDPE基体之间存在着良好的相互作用,不仅在其伸长率达到600%时仍未断裂,而且在各点上的拉伸应力值均大于纯HDPE,对制备HDPE/PS纳米合金或其他HDPE改性材料应为较理想的条件，

关键词：纳米合金扩散相形态高密度聚乙烯聚苯乙烯

Site testing campaign for the Large Optical/infrared Telescope of China:overview

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第6期20卷 81-95页

作者： Lu Feng Jin-Xin Hao Zi-Huang Cao Jin-Min Bai Ji Yang Xu Zhou Yong-Qiang yao Jin-Liang Hou Yong-Heng zhao yu Liu Teng-Fei Song Li-Yong Liu Jia Yin Hua-Lin chen Chong Pei Ali Esamdin Lu Ma Chun-Hai Bai Peng Wei Jing Xu Guang-Xin Pu guo-Jie Feng Xuan Zhang Liang Ming Abudusaimaitijiang Yisikandee jian-rong Shi jian Li yuan Tian Zheng Wang xia Wang xiao-Jun jiang jian-Feng Wang jian-Feng Tian Yan-Jie xue jian-Sheng chen Jing-yao Hu Zhi-xia Shen yun-Ying jiang National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China yunnan Observatories Chinese Academy of SciencesKunming 650216China Xinjiang Astronomical Observatory Chinese Academy of SciencesUrumqi 830011China Shanghai Astronomical Observatory Chinese Academy of SciencesShanghai 200030China Nanjing Institute of Astronomical Optics&Technology Chinese Academy of SciencesNanjing 210042China Purple Mountain Observatory Chinese Academy of SciencesNanjing 210033China University of Chinese Academy of Sciences Beijing 100049China

The Large Optical/infrared Telescope(LOT)is a ground-based 12 m diameter optical/infrared telescope which is proposed to be built in the western part of China in the next *** on satellite remote sensing data,along with geographical,logistical and political considerations,three candidate sites were chosen for ground-based astronomical performance *** sites include:Ali in Tibet,Daocheng in Sichuan and Muztagh-ata in *** until now,all three sites have continuously collected data for two *** this paper,we will introduce this site testing campaign,and present its monitoring results obtained during the period between March 2017 and March 2019.

关键词： techniques telescope-site testing

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-Jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang guofu Cao jianshe Cao Antoine Chance xuejun Chang yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che yuzhi Che Bin chen Danping chen Fuqing chen Fusan chen Gang chen guoming chen Hua-Xing chen Huirun chen Jinhui chen Ji-yuan chen Kai chen Mali chen Mingjun chen Mingshui chen Ning chen Shanhong chen Shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen xiang chen xiaoyu chen Xin chen Xun chen Xurong chen Ye chen Ying chen yukai chen Zelin chen Zilin chen Gang chen Boping chen Chunhui chen Hok Chuen cheng Huajie cheng Shan cheng Tongguang cheng yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui zhaoyuan Cui Brunella D'Anzi Ling-yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： Ying-Hui Jin Qing-yuan Zhan Zhi-Yong Peng xue-Qun Ren Xun-Tao Yin Lin Cai yu-Feng yuan Ji-rong yue xiao-Chun Zhang Qi-Wen Yang jianguang Ji jian xia Yi-rong Li Fu-xiang Zhou Ya-Dong Gao Zhui yu Feng Xu Ming-Li Tu Li-Ming Tan Min Yang fang chen xiao-Ju Zhang Mei Zeng yu Zhu Xin-Can Liu jian Yang Dong-Chi zhao yu-Feng Ding Ning Hou Fu-Bing Wang Hao chen Yong-Gang Zhang Wei Li Wen chen yue-xian Shi Xiu-Zhi Yang xue-Jun Wang Yan-Jun Zhong Ming-Juan zhao Bing-Hui Li Lin-Lu Ma Hao Zi Na Wang yun-yun Wang Shao-Fu yu Lu-yao Li Qiao Huang Hong Weng xiang-Ying Ren Li-Sha Luo Man-Ru Fan Di Huang Hong-Yang xue Lin-Xin yu Jin-Ping Gao Tong Deng xian-Tao Zeng Hong-Jun Li Zhen-Shun cheng xiao-Mei yao Xing-Huan Wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

Data processing and data products from 2017 to 2019 campaign of astronomical site testing at Ali,Daocheng and Muztagh-ata

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第6期20卷 109-130页

作者： Zi-Huang Cao Jin-Xin Hao Lu Feng Hugh RAJones jian Li Jing Xu Li-Yong Liu Teng-Fei Song jian-Feng Wang Hua-Lin chen Yan-Jie xue Huang Shen Yong-Heng zhao zhao-xiang Qi jian-rong Shi yuan Tian Zheng Wang xia Wang Jin-Liang Hou Jin-Ming Bai Ji Yang Xu Zhou Yong-Qiang yao Jia Yin Ali Esamdin Guang-Xin Pu Peng Wei Chun-Hai Bai guo-Jie Feng Lu Ma Xuan Zhang yu Liu Chong Pei Zhi-xia Shen yun-Ying jiang jian-Feng Tian xian-Qun Zeng Zhi-Gang Hou Xu Yang Jun-Bo Zhang Shi-Long Liao Dong-Wei Fan yun-Fei Xu jian-Ping Xiong Tai-Sheng Yan Xi Zhang Chang-Hua Li Yi-Han Tao Si-cheng yu Zhi-Song Cao Hong-Shuai Wang National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100049China Shanghai Astronomical Observatory Chinese Academy of SciencesShanghai 200030China Centre for Astrophysics University of HertfordshireHatfieldUK School of Journalism Communication University of ChinaBeijing 100024China Nanjing Institute of Astronomical Optics&Technology Chinese Academy of SciencesNanjing 210042China Xinjiang Astronomical Observatory Chinese Academy of SciencesUrumqi 830011China yunnan Observatories Chinese Academy of SciencesKunming 650216China Purple Mountain Observatory Chinese Academy of SciencesNanjing 210033China Beijing Kaiyang Space Technology Co. LtdBeijing 100085China

Based on previous site testing and satellite cloud data,Ali,Daocheng and Muztagh-ata have been selected as candidate sites for the Large Optical/Infrared Telescope(LOT) in *** present the data collection,processing,management and quality analysis for our site testing based on using similar *** analyze meteorological data,seeing,background light,cloud and precipitable water vapor data from 2017 March 10 to 2019 March *** also investigated the relative usefulness of our all-sky camera data in comparison to that from the meteorological TERRA satellite data based on a night-by-night comparison of the correlation and consistency between *** find a 6% discrepancy arising from a wide range of factors.

关键词： LOT Site-selection-data processing

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： Jun Liu Dan-Dan Li Wei Dong yu-Qi Liu Yang Wu Da-Xuan Tang Fu-Chun Zhang Meng Qiu Qi Hua Jing-yu He Jun Li Bai Du Ting-Hai Du Lin-Lin Niu xue-Jun jiang Bo Cui jiang-Bin chen Yang-Gan Wang Hai-rong Wang Qin yu Jing He Yi-Lin Mao xiao-fang Bin yue Deng yu-Dan Tian Qing-Hua Han Da-Jin Liu Li-Qin Duan Ming-Jun zhao Cui-Ying Zhang Hai-Ying Dai Ze-Hua Li Ying xiao You-Zhi Hu xiao-yu Huang Kun Xing Xin jiang Chao-Feng Liu Jing An Feng-Chun Li Tao Tao Jin-Fa jiang Ying Yang yao-rong Dong Lei Zhang Guang Fu Ying Li Shu-Wei Huang Li-Ping Dou Lan-Jun Sun Ying-Qiang zhao Jie Li yun xia Jun Liu Fan Liu Wen-Jin He Ying Li jian-Cong Tan Yang Lin Ya-Bin Zhou jian-Fei Yang guo-Qing Ma Hui-Jun chen He-Ping Liu Zong-Wu Liu jian-Xiong Liu xiao-Jia Luo xiao-Hong Bin Ya-Nan yu Hai-xia Dang Bing Li Fei Teng Wang-Min Qiao xiao-Long Zhu Bing-Wei chen Qi-Guang chen Chun-Ti Shen Yong-Yan Wang yun-Dai chen Zhong Wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

The Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2012年第9期12卷 1197-1242页

作者： xiang-Qun Cui Yong-Heng zhao yao-Quan Chu guo-Ping Li Qi Li Li-Ping Zhang Hong-Jun Su Zheng-Qiu yao Ya-Nan Wang xiao-Zheng Xing Xin-Nan Li Yong-Tian Zhu Gang Wang Bo-Zhong Gu A-Li Luo Xin-Qi Xu Zhen-Chao Zhang Gen-rong Liu Hao-Tong Zhang De-Hua Yang Shu-yun Cao Hai-yuan chen jian-Jun chen Kun-Xin chen Ying chen Jia-Ru Chu Lei Feng xue-Fei Gong Yong-Hui Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu Lei Jia fang-Hua jiang xiang jiang Zi-Bo jiang Ge Jin Ai-Hua Li Yan Li Ye-Ping Li Guan-QunLiu Zhi-Gang Liu Huo-Ming Shi Zheng-Hong Tang Qing-Sheng Tao xiang-Yan yuan Chao Zhai Jing Zhang Yan-xia Zhang Yong Zhang Ming zhao fang Zhou guo-Hua Zhou Jie Zhu Si-cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China yzhao @ *** Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Tecfinologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture Design and Research Chinese Academy of Sciences Beijing 100190China

The Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST, also called the guo Shou Jing Telescope) is a special reflecting Schmidt telescope. LAMOST’s special design allows both a large aperture (effective aperture of 3.6 m–4.9 m) and a wide field of view (FOV) (5°). It has an innovative active reflecting Schmidt configuration which continuously changes the mirror’s surface that adjusts during the observation process and combines thin deformable mirror active optics with segmented active optics. Its primary mirror (6.67m×6.05 m) and active Schmidt mirror (5.74m×4.40 m) are both segmented, and composed of 37 and 24 hexagonal sub-mirrors respectively. By using a parallel controllable fiber positioning technique, the focal surface of 1.75 m in diameter can accommodate 4000 optical fibers. Also, LAMOST has 16 spectrographs with 32 CCD cameras. LAMOST will be the telescope with the highest rate of spectral acquisition. As a national large scientific project, the LAMOST project was formally proposed in 1996, and approved by the Chinese government in 1997. The construction started in 2001, was completed in 2008 and passed the official acceptance in June 2009. The LAMOST pilot survey was started in October 2011 and the spectroscopic survey will launch in September 2012. Up to now, LAMOST has released more than 480 000 spectra of objects. LAMOST will make an important contribution to the study of the large-scale structure of the Universe, structure and evolution of the Galaxy, and cross-identification of multiwaveband properties in celestial objects.

关键词： techniques: wide field telescope - active optics - multi fiber - spectroscopy survey - data reduction

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li Luo Yong-Heng zhao Gang zhao Li-Cai Deng xiao-Wei Liu Yi-Peng Jing Gang Wang Hao-Tong Zhang jian-rong Shi xiang-Qun Cui yao-Quan Chu guo-Ping Li Zhong-Rui Bai yue Wu Yan Cai Shu-yun Cao Zi-Huang Cao Jeffrey L.Carlin Hai-yuan chen jian-Jun chen Kun-Xin chen Li chen xue-Lei chen xiao-Yan chen Ying chen Norbert Christlieb Jia-Ru Chu chen-Zhou Cui Yi-Qiao Dong Bing Du Dong-Wei Fan Lei Feng jian-Ning Fu Peng Gao xue-Fei Gong Bo-Zhong Gu Yan-Xin guo Zhan-Wen Han Bo-Liang He Jin-Liang Hou Yong-Hui Hou Wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu Zhi-Ying Huo Lei Jia fang-Hua jiang xiang jiang Zhi-Bo jiang Ge Jin xiao Kong Xu Kong Ya-Juan Lei Ai-Hua Li Chang-Hua Li Guang-Wei Li Hai-Ning Li jian Li Qi Li Shuang Li Sha-Sha Li Xin-Nan Li Yan Li Yin-Bi Li Ye-Ping Li yuan Liang Chien-cheng Lin Chao Liu Gen-rong Liu Guan-Qun Liu Zhi-Gang Liu Wen-Zhi Lu yu Luo Yin-Dun Mao Heidi Newberg Ji-Jun Ni zhao-xiang Qi Yong-Jun Qi Shi-Yin Shen Huo-Ming Shi Jing Song Yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-Sheng Tao yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang guo-Min Wang Hai Wang Hong-Chi Wang jian Wang Jia-Ning Wang jian-Ling Wang jian-Ping Wang Jun-xian Wang Lei Wang Meng-Xin Wang Shou-Guan Wang Shu-Qing Wang xia Wang Ya-Nan Wang You Wang yue-Fei Wang You-Fen Wang Peng Wei Ming-Zhi Wei Hong Wu Ke-Fei Wu xue-Bing Wu yu-Zhong Wu xiao-Zheng Xing Ling-Zhe Xu Xin-Qi Xu Yan Xu Tai-Sheng Yan De-Hua Yang Hai-Feng Yang Hui-Qin Yang Ming Yang Zheng-Qiu yao Yong yu Hui yuan Hai-Bo yuan Hai-Long yuan Wei-Min yuan Chao Zhai En-Peng Zhang Hua-Wei Zhang jian-Nan Zhang Li-Pin Zhang Wei Zhang Yong Zhang Yan-xia Zhang Zheng-Chao Zhang Ming zhao fang Zhou Xu Zhou Jie Zhu Yong-Tian Zhu Si-cheng Zou fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第6期6卷 1845-1855页

作者： Huijie Bian zhao-Hui Zheng Ding Wei Aidong Wen Zheng Zhang jian-Qi Lian Wen-Zhen Kang Chun-Qiu Hao Jing Wang rong-Hua Xie Ke Dong Jie-Lai xia Jin-Lin Miao Wen Kang guoquan Li Di Zhang Mingru Zhang Xiu-Xuan Sun Likun Ding Kui Zhang Junfeng Jia Jin Ding Zhiqin Li Yanyan Jia Lin-Na Liu Zhe Zhang zhao-Wei Gao Hong Du Na yao Qing Wang Ke Wang Jie-Jie Geng Bin Wang Ting guo Ruo chen yu-Meng Zhu Li-Juan Wang Qian He Rui-Rui yao Ying Shi xiang-Min Yang jian-Sheng Zhou Yi-Nan Ma Ya-Tao Wang xue Liang Fei Huo Zhe Wang Yang Zhang Xu Yang Ye Zhang Lu-Hua Gao Ling Wang xiao-Chun chen Hao Tang Shuang-Shuang Liu Qing-Yi Wang Zhi-Nan chen Ping Zhu National Translational Science Center for Molecular Medicine and Department of Cell Biology Fourth Military Medical UniversityXi'anChina Department of Clinical Immunology Xijing HospitalFourth Military Medical UniversityXi'anChina Department of Pharmacy Xijing HospitalFourth Military Medical UniversityXi'anChina Center for Infectious Diseases Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Nuclear Medicine Xijing HospitalFourth Military Medical UniversityXi'anChina department of Clinical Diagnosis Tangdu HospitalFourth Military Medical UniversityXKanChina College of Military Preventive Medicine Fourth Military Medical UniversityXi'anChina Department of Pharmaceutics Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Pathology Fourth Military Medical UniversityXi'anChina jiangsu Pacific Meinuoke Biopharmaceutical Co.Ltd ChangzhouChina Department of Foreign Languages Fourth Military Medical UniversityXi'anChina

Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)*** CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 *** is a humanized anti-CD147 IgG_(2) monoclonal antibody,which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019(COVID-19)***,we conducted a randomized,double-blinded,placebo-controlled phase 1 trial to evaluate the safety,tolerability,and pharmacokinetics of meplazumab in healthy subjects,and an open-labeled,concurrent controlled add-on exploratory phase 2 study to determine the efficacy in COVID-19 *** phase 1 study,59 subjects were enrolled and assigned to eight cohorts,and no serious treatment-emergent adverse event(TEAE)or TEAE grade≥3 was *** serum and peripheral blood Cmax and area under the curve showed non-linear pharmacokinetic *** obvious relation between the incidence or titer of positive anti-drug antibody and dosage was observed in each *** biodistribution study indicated that meplazumab reached lung tissue and maintained>14 days stable with the lung tissue/cardiac blood-pool ratio ranging from 0.41 to *** the exploratory phase 2 study,17 COVID-19 patients were enrolled,and 11 hospitalized patients were involved as concurrent *** meplazumab treatment significantly improved the discharged(P=0.005)and case severity(P=0.021),and reduced the time to virus negative(P=0.045)in comparison to the control *** results show a sound safety and tolerance of meplazumab in healthy volunteers and suggest that meplazumab could accelerate the recovery of patients from COVID-19 pneumonia with a favorable safety profile.

关键词： patients dosage phase